Intellia Therapeutics Inc [NASDAQ: NTLA] price surged by 8.60 percent to reach at $0.85.
The one-year NTLA stock forecast points to a potential upside of 70.87. The average equity rating for NTLA stock is currently 1.62, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Intellia Therapeutics Inc [NTLA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NTLA shares is $36.84 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NTLA stock is a recommendation set at 1.62. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Intellia Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 21, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 05, 2025, representing the official price target for Intellia Therapeutics Inc stock. Previously, the target price had yet another drop from $45 to $13, while JP Morgan kept a Neutral rating on NTLA stock.
The Price to Book ratio for the last quarter was 1.42, with the Price to Cash per share for the same quarter was set at 4.86.
NTLA Stock Performance Analysis:
Intellia Therapeutics Inc [NTLA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.24. With this latest performance, NTLA shares gained by 49.86% in over the last four-week period, additionally sinking by -10.36% over the last 6 months – not to mention a drop of -7.98% in the past year of trading.
Insight into Intellia Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Intellia Therapeutics Inc [NTLA] shares currently have an operating margin of -1173.09% and a Gross Margin at 77.46%. Intellia Therapeutics Inc’s Net Margin is presently recorded at -1154.10%.
Return on Equity for this stock declined to -46.84%, with Return on Assets sitting at -46.84%.
NTLA Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NTLA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Intellia Therapeutics Inc go to 31.48%.
Intellia Therapeutics Inc [NTLA] Institutonal Ownership Details
The top three institutional holders of NTLA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 11.6 million shares, which is approximately 11.9575%. BLACKROCK INC., holding 9.6 million shares of the stock with an approximate value of $$214.79 million in NTLA stocks shares; and BLACKROCK INC., currently with $$203.66 million in NTLA stock with ownership which is approximately 9.3839%.
